新闻源 财富源

2019年10月18日 星期五

誉衡药业(002437)公告正文

誉衡药业:2016年第三季度报告全文

公告日期:2016-10-22

  哈尔滨誉衡药业股份有限公司


证券代码:002437                  证券简称:誉衡药业   公告编号:2016-156




                          哈尔滨誉衡药业股份有限公司

                               2016 年第三季度报告




                                  2016 年 10 月




                                        第1页
   哈尔滨誉衡药业股份有限公司




                                        第一节 重要提示

    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整,不存在虚假记载、误导性陈
述或者重大遗漏,并承担个别和连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人朱吉满、主管会计工作负责人刁秀强及会计机构负责人(会计主管人员)刘文才声明:保证季度报告中财务报
表的真实、准确、完整。




                                                   第2页
   哈尔滨誉衡药业股份有限公司




                             第二节 主要财务数据及股东变化

一、主要会计数据和财务指标

公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据
□ 是 √ 否

                                          本报告期末                    上年度末            本报告期末比上年度末增减

总资产(元)                                8,437,255,895.44            8,312,681,074.32                          1.50%

归属于上市公司股东的净资产(元)            3,800,941,908.52            3,415,321,704.49                          11.29%

                                                          本报告期比上年同期                            年初至报告期末
                                        本报告期                                   年初至报告期末
                                                                 增减                                   比上年同期增减

营业收入(元)                           734,361,228.36                 10.77%       2,071,429,028.58             7.46%

归属于上市公司股东的净利润(元)         216,041,965.19                 23.18%         557,832,822.01             11.77%

归属于上市公司股东的扣除非经常性
                                         186,579,906.58                 17.15%         507,933,801.67             8.09%
损益的净利润(元)

经营活动产生的现金流量净额(元)            --                    --                   572,873,243.24             -4.52%

基本每股收益(元/股)                            0.0983                 23.18%                 0.2537             11.71%

稀释每股收益(元/股)                            0.0983                 23.18%                 0.2537             11.71%

加权平均净资产收益率                             6.28%                   1.06%                 15.45%             0.00%

注:2016 年 5 月,公司实施了以每 10 股送 10 股、派 2.5 元人民币,同时以资本公积金向全体股东每 10 股转增 10 股的权
益分配方案,公司根据企业会计准则的相关规定按照最新股本调整并列报基本每股收益与稀释每股收益情况。
截止披露前一交易日的公司总股本:

截止披露前一交易日的公司总股本(股)                                                                       2,198,290,350

                                                                  本报告期                       年初至报告期末

用最新股本计算的全面摊薄每股收益(元/股)                                          0.0983                         0.2538

非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                                 单位:元

                             项目                                 年初至报告期期末金额                   说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                        -2,806,043.13 固定资产处置损失

计入当期损益的政府补助(与企业业务密切相关,按照国家统一标准                                  其中,拉萨市曲水县政府企
                                                                              53,845,089.70
定额或定量享受的政府补助除外)                                                                业发展基金 4,081.72 万元

除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融
资产、交易性金融负债产生的公允价值变动损益,以及处置交易性金                     3,771,679.89 银行理财产品收益
融资产、交易性金融负债和可供出售金融资产取得的投资收益



                                                       第3页
   哈尔滨誉衡药业股份有限公司


除上述各项之外的其他营业外收入和支出                                              998,070.75

减:所得税影响额                                                                 6,002,053.41

    少数股东权益影响额(税后)                                                     -92,276.54

合计                                                                          49,899,020.34                --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                                   单位:股

                                                            报告期末表决权恢复的优先
报告期末普通股股东总数                             43,588                                                                0
                                                            股股东总数(如有)

                                                前 10 名股东持股情况

                                                                                 持有有限售条         质押或冻结情况
             股东名称                  股东性质       持股比例     持股数量
                                                                                 件的股份数量 股份状态            数量

哈尔滨誉衡集团有限公司             境内非国有法人       42.63%     937,125,000                   0 质押         722,837,226

YU HENG INTERNATIONAL
                                   境外法人             19.54%     429,578,904                   0 质押         164,180,000
INVESTMENTS CORPORATION

ORIENTAL KEYSTONE
                                   境外法人              1.95%      42,904,599                   0
INVESTMENT LIMITED

杨红冰                             境内自然人            0.89%      19,605,000        14,703,750

中央汇金资产管理有限责任公司       国有法人              0.72%      15,767,700                   0

尹美娟                             境内自然人            0.60%      13,293,868                   0

中铁宝盈资产-工商银行-中铁宝盈
                                   其他                  0.60%      13,165,110                   0
-宝鑫 88 号特定客户资产管理计划

广发证券资管-浦发银行-广发资管
                                   其他                  0.52%      11,403,300                   0
晴天 1 号集合资产管理计划

韦秀萍                             境内自然人            0.47%      10,340,451                   0

朱吉满                             境内自然人            0.45%       9,967,500         9,967,500

                                          前 10 名无限售条件股东持股情况

                                                                                                      股份种类
                     股东名称                            持有无限售条件股份数量
                                                                                                股份种类         数量


                                                       第4页
   哈尔滨誉衡药业股份有限公司


哈尔滨誉衡集团有限公司                                                  937,125,000 人民币普通股      937,125,000

YU HENG INTERNATIONAL INVESTMENTS
                                                                        429,578,904 人民币普通股      429,578,904
CORPORATION

ORIENTAL KEYSTONE INVESTMENT LIMITED                                     42,904,599 人民币普通股       42,904,599

中央汇金资产管理有限责任公司                                             15,767,700 人民币普通股       15,767,700

尹美娟                                                                   13,293,868 人民币普通股       13,293,868

中铁宝盈资产-工商银行-中铁宝盈-宝鑫 88 号特定
                                                                         13,165,110 人民币普通股       13,165,110
客户资产管理计划

广发证券资管-浦发银行-广发资管晴天 1 号集合资产
                                                                         11,403,300 人民币普通股       11,403,300
管理计划

韦秀萍                                                                   10,340,451 人民币普通股       10,340,451

尹江                                                                      9,548,890 人民币普通股        9,548,890

宋晓文                                                                    8,497,116 人民币普通股        8,497,116

                                                    1、哈尔滨誉衡集团有限公司、YU HENG INTERNATIONAL
                                                    INVESTMENTS CORPORATION 以及 ORIENTAL KEYSTONE
                                                    INVESTMENT LIMITED 由同一实际控制人朱吉满控制。
                                                    2、实际控制人朱吉满通过《中铁宝盈资产-工商银行-中铁宝盈
上述股东关联关系或一致行动的说明                    -宝鑫 88 号特定客户资产管理计划》持有公司 13,165,110 股股票。
                                                    3、实际控制人朱吉满通过《广发证券资管-浦发银行-广发资管
                                                    晴天 1 号集合资产管理计划》持有公司 11,403,300 股股票。
                                                    4、未知其他股东是否存在关联关系,也未知是否属于《上市公司
                                                    收购管理办法》中规定的一致行动人。

                                                  1、尹美娟通过融资融券业务持有公司股票 12,306,768 股。
前 10 名普通股股东参与融资融券业务情况说明(如有)
                                                  2、韦秀萍通过融资融券业务持有公司股票 10,340,451 股。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                     第5页
     哈尔滨誉衡药业股份有限公司




                                               第三节 重要事项

一、报告期主要会计报表项目、财务指标发生变动的情况及原因

√ 适用 □ 不适用
1、2016年9月30日资产负债表项目

       项目            期末余额           期初余额        变动率                            原因说明
应收账款             138,467,055.84      97,725,677.96     41.69%    主要系本期销售业务信用政策调整所致
预付账款             193,837,624.38     118,939,646.04     62.97%    主要系本期预付货款业务增加所致
应收利息                2,941,594.94        205,402.28    1332.11%   主要系本期应收定期存款利息增加所致
                                                                     主要系本期收回天津赛诺制药有限公司独家代理保证
其他应收款           123,308,326.61     288,820,335.42     -57.31%
                                                                     金所致
其他流动资产          65,176,945.59      40,789,464.54     59.79%    主要系待抵扣的增值税和预缴的企业所得税增加所致
                                                                     系本期增加对上海赛领博达科尔投资合伙企业、Proteus
可供出售金融                                                         Digital Health, Inc、WuXi Healthcare Ventures II, L.P.、
                     315,013,606.80      25,273,136.80    1146.44%
资产                                                                 浙江聚有财金融服务外包有限公司(以下简称“聚有
                                                                     财”)投资所致
其他非流动资
                     200,757,879.66     305,670,020.07     -34.32%   主要系部分预付固定资产的款项已转固定资产所致

应付票据                1,450,000.00     91,870,932.61     -98.42%   主要系本期票据到期承兑所致
应付账款             142,537,404.62      95,480,858.12     49.28%    主要系本期采购信用付款业务增加所致

应付职工薪酬            4,829,440.46       7,227,946.40    -33.18%   主要系上年计提的年终奖金在本年发放所致

                                                                     主要系控股股东一致行动人同意延期支付本期现金分
应付股利              84,705,672.75      11,393,210.00    643.48%
                                                                     红款所致
                                                                     一年以内应支付的山西普德药业有限公司(以下简称
一年内到期的
                    1,097,227,078.96   1,618,630,463.16    -32.21%   “普德药业”)和上海华拓医药科技发展有限公司原股
非流动负债
                                                                     东股权购买尾款减少所致
                                                                     系逐步优化长短期借款的配置,增加2年期银行借款所
长期借款             961,008,334.50     300,000,000.00    220.34%
                                                                     致
                                                                     一年以上应支付的普德药业原股东股权购买尾款减少
长期应付款            33,340,000.00     456,548,563.61     -92.70%
                                                                     所致
                                                                     主要系资本公积转增股本及股票股利分配增加股份所
股本                2,198,290,350.00    733,009,500.00    199.90%
                                                                     致
资本公积             339,638,971.85    1,063,791,333.73    -68.07%   主要系转增股本减少资本公积所致
库存股                  1,659,876.08       4,328,082.48    -61.65%   主要系股权激励计划回购股份所致
2、2016年1-9月利润表项目
       项目           本期发生额         上期发生额       变动率                            原因说明
销售费用              162,482,911.07    258,382,631.54     -37.12%   主要系本期部分产品在福建未中标,导致销售费用下降
资产减值损失            3,323,953.04        897,775.97    270.24%    主要系本期部分存货计提跌价准备所致
                                                                     主要系本期誉衡金融服务(深圳)有限公司(以下简称
投资收益               10,587,623.36      4,313,175.54    145.47%
                                                                     "誉衡金服")股权转让产生的投资收益增加所致

                                                           第6页
     哈尔滨誉衡药业股份有限公司


营业外收入              56,686,364.34   31,529,278.16      79.79%     主要系本期政府补助项目增加所致
营业外支出               4,649,247.02      424,565.39     995.06%     主要系本期固定资产报废所致

3、2016年1-9月现金流量表项目

       项目          本期发生额         上期发生额        变动率                          原因说明
支付给职工以
及为职工支付         247,720,493.13     188,515,024.90     31.41%     主要系本期职工薪酬的增加所致
的现金
处置子公司及
其他营业单位
                      28,693,020.11               0.00    100.00%     系本期出售誉衡金服股权收到的现金所致
收到的现金净

收到其他与投
                                                                      系本期收到拟出售普德药业股权的定金及收回的拟收
资活动有关的          75,000,000.00               0.00    100.00%
                                                                      购湖北多瑞药业有限公司股权的定金所致
现金
吸收投资收到                                                          系本期宁波誉东健康科技有限公司收到股东江苏京东
                      15,000,000.00               0.00    100.00%
的现金                                                                邦能投资管理有限公司投入的现金所致
收到其他与筹
                                                                      主要系本期收到票据承兑保证金及贷款保证金增加所
资活动有关的         133,804,846.61      49,000,000.00    173.07%
                                                                      致
现金
偿还债务支付
                    1,299,000,000.00    980,000,000.00     32.55%     主要系本期偿还银行贷款增加所致
的现金
分配股利、利
                                                                      主要系本期分配股利增加及支付银行贷款利息增加所
润或偿付利息         189,463,927.60     139,444,916.56     35.87%
                                                                      致
支付的现金
支付其他与筹
资活动有关的         175,641,024.00      68,815,201.14    155.24%     主要系本期支付贷款保证金增加所致
现金


二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用
       1、已发布临时公告的重要事项

                重要事项概述                         披露日期                    临时报告披露网站查询索引

                                                                    详见发布在《中国证券报》、《证券时报》及巨潮资讯网
公司获得新版 GMP 证书(认证范围:进口药
                                              2016 年 07 月 15 日 www.cninfo.com.cn(以下简称“指定披露媒体”)的
品分包装(注射剂、治疗用生物制品))
                                                                    2016-128 号公告《关于公司获得新版 GMP 证书的公告》。

公司参股公司陕西佰美基因股份有限公司在                              详见发布在指定披露媒体的 2016-133 号公告《关于参股
                                              2016 年 08 月 11 日
全国中小企业股份转让系统挂牌交易。                                  公司在全国中小企业股份转让系统挂牌交易的公告》。

公司全资子公司广州市新花城生物科技有限                              详见发布在指定披露媒体的 2016-136 号公告《关于全资
                                              2016 年 08 月 29 日
公司拟进行分立。                                                    子公司广州市新花城生物科技有限公司分立的公告》。

聚有财以人民币 3,500 万元及其 5%的股权作                     详见发布在指定披露媒体的 2016-137 号公告《关于拟转
                                         2016 年 08 月 29 日
为对价,受让公司持有的誉衡金服 100%股权。                    让誉衡金融服务(深圳)有限公司股权的公告》。


                                                           第7页
   哈尔滨誉衡药业股份有限公司


截至报告期末,誉衡金服务已完成股权转让的
                                                                   详见发布在指定披露媒体的 2016-149 号公告《关于转让
工商变更,誉衡金服及子公司不再纳入公司合 2016 年 09 月 30 日
                                                                   誉衡金融服务(深圳)有限公司股权的进展公告》。
并报表范围。

    2、报告期内发生的其他事项
    ⑴ 取得注册批件
    报告期内,公司全资子公司普德药业的盐酸法舒地尔(原料药)取得CFDA签发的药品注册批件(药品批件号:
2016S00352),盐酸法舒地尔适应症为改善和预防蛛网膜下腔出血术后的脑血管痉挛及引起的脑缺血症状,是该领域临床
主流用药之一,属于国家医保乙类产品。本次获得盐酸法舒地尔的注册批件,将打破此前单纯依靠外部采购原料的局面,有
助于公司进一步整合本品上下游产业链,降低生产成本,提升市场竞争力。同时,在严峻的审评、审批环境下顺利获得盐酸
法舒地尔注册批件,一定程度上证明了公司在仿制药开发方面的技术水平。
    ⑵ 推进招标落地
    报告期内,公司继续推进各省市的药品招标工作,主要产品取得如下进展:鹿瓜多肽注射液在湖北、内蒙古、山东、广
西新中标,磷酸肌酸钠在黑龙江、广西、青海、山东、内蒙古新中标,安脑丸/片在陕西、山东、广东、广西、上海新中标;
葡萄糖酸钙锌口服溶液在山东、广东新中标;氯吡格雷在广东、陕西、广西、内蒙古、山东、河北新中标,DNA在河北、
内蒙古、广西、湖北、天津新中标,重组人胰岛素注射液在天津、河北、山东、陕西、青海、内蒙古新中标;精蛋白重组人
胰岛素注射液在天津、河北、内蒙古、山东、青海、广西、陕西新中标。
    ⑶ 荣获多项荣誉
    报告期内,公司在中国医药工业信息中心主办的第33届全国医药工业信息年会上,荣获“2015年度中国医药工业百强”、
“2016年中国医药工业最具成长力企业”称号。
    报告期内,公司入选CFDA南方医药经济研究所公布的“2015年中国制药工业百强榜”,位列全国第64位。
    报告期内,公司产品葡萄糖酸钙锌口服溶液荣登2016“健康中国品牌榜”,品类:儿童维生素矿物质补充用药品类。
    报告期内,公司荣获“2015年度上市公司金牛奖百强”荣誉。
    3、期后事项

               期后事项概述                   披露日期                      临时报告披露网站查询索引
公司拟设立全资子公司誉衡(北京)投资
                                                            详见发布在指定披露媒体的2016-051号公告《关于设立誉衡(北
有限公司,作为公司总部职能机构及资产 2016年10月10日
                                                            京)投资有限公司的公告》。
管理、投融资管理、股权管理平台。
公司拟参与设立苏州工业园区原点正则贰                        详见发布在指定披露媒体的2016-052号公告《关于拟参与设立
                                          2016年10月10日
号创业投资企业(有限合伙)。                                苏州工业园区原点正则贰号创业投资企业(有限合伙)的公告》。


三、公司、股东、实际控制人、收购人、董事、监事、高级管理人员或其他关联方在报告期
内履行完毕及截至报告期末尚未履行完毕的承诺事项

√ 适用 □ 不适用

     承诺事由        承诺方 承诺类型                        承诺内容                    承诺时间 承诺期限 履行情况

                                         承诺其持有权益达 50%以上或实际控制的企业
                              关于同业
                                         或单位(“附属公司”)目前并没有直接或间接地从
                    哈尔滨 竞争、关
                                         事任何与公司实际从事的业务发生利益冲突或
首次公开发行或再 誉衡集 联交易、                                                        2010 年 06          正常履行
                                         在市场、资源、地域方面存在竞争的任何业务活                  长期
融资时所作承诺      团有限 资金占用                                                     月 23 日            中
                                         动。其及其附属公司在今后的任何时间不会直接
                    公司      方面的承
                                         或间接地以任何方式(包括但不限于自营、合资或
                              诺
                                         联营)参与或进行与公司实际从事的业务存在直

                                                           第8页
   哈尔滨誉衡药业股份有限公司


                                       接或间接竞争的任何业务活动(与公司合作开发
                                       除外)。凡其及其附属公司有任何商业机会可从
                                       事、参与或入股任何可能会与公司生产经营构成
                                       竞争的业务,会将上述商业机会优先让予公司。

                                       承诺其及其实际控制的企业或单位(“附属公司”)
                                       目前并没有直接或间接地从事任何与公司实际
                                       从事的业务发生利益冲突或在市场、资源、地域
                            关于同业
                                       方面存在竞争的任何业务活动。其及其附属公司
                            竞争、关
                                       在今后的任何时间不会直接或间接地以任何方
                   朱吉满;联交易、                                                   2010 年 06             正常履行
                                       式(包括但不限于自营、合资或联营)参与或进行                  长期
                   白莉惠 资金占用                                                    月 23 日               中
                                       与公司实际从事的业务存在直接或间接竞争的
                            方面的承
                                       任何业务活动(与公司合作开发除外)。其及其附
                            诺
                                       属公司有任何商业机会可从事、参与或入股任何
                                       可能会与公司生产经营构成竞争的业务,会将上
                                       述商业机会优先让予公司。

                   朱吉满、            限售期届满后,在担任公司董事、监事或高管人
                   白莉惠、股份限售 员期间,每年转让的股份不超过所间接持有公司 2010 年 06                    正常履行
                                                                                                   长期
                   王东绪、承诺        股份总数的 25%;离职后半年内,不转让所间接 月 23 日                   中
                   杨红冰              持有的公司股份。

                            股份限售 限制性股票激励计划授予对象朱吉满先生承诺         2014 年 10             正常履行
股权激励承诺       朱吉满                                                                          36 个月
                            承诺       所获股票自授予日起三十六个月内不得转让。       月 31 日               中

承诺是否按时履行 是

如承诺超期未履行
完毕的,应当详细
说明未完成履行的 不适用
具体原因及下一步
的工作计划


四、对 2016 年度经营业绩的预计

2016 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2016 年度归属于上市公司股东的净利润变动幅度                                 5.00%      至                         20.00%

2016 年度归属于上市公司股东的净利润变动区间(万元)                      71,086.87     至                     81,242.14

2015 年度归属于上市公司股东的净利润(万元)                                                                   67,701.78

                                                       1、夯实传统制药板块业务,实现平稳增长;
                                                       2、调整优化公司产品格局,代理产品成为新的盈利增长点;
                                                       3、慢病、生物药等新业务的投入,短期内对公司盈利产生一定
业绩变动的原因说明
                                                       的影响;
                                                       4、由于国家新药审批政策调整,公司已/拟终止部分研发项目,
                                                       将对公司利润产生一定的影响。


                                                       第9页
   哈尔滨誉衡药业股份有限公司


五、以公允价值计量的金融资产

□ 适用 √ 不适用


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、报告期内接待调研、沟通、采访等活动登记表

√ 适用 □ 不适用

     接待时间        接待方式     接待对象类型                         调研的基本情况索引

2016 年 09 月 06 日 实地调研     机构            详见 2016 年 9 月 6 日发布的《投资者关系活动记录表》




                                                     第 10 页
   哈尔滨誉衡药业股份有限公司




                                       第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:哈尔滨誉衡药业股份有限公司
                                         2016 年 09 月 30 日
                                                                                              单位:元

                 项目                         期末余额                        期初余额

流动资产:

    货币资金                                              880,915,211.21            1,193,363,406.18

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当期
损益的金融资产

    衍生金融资产

    应收票据                                               33,711,231.52                 37,860,195.21

    应收账款                                              138,467,055.84                 97,725,677.96

    预付款项                                              193,837,624.38             118,939,646.04

    应收保费

    应收分保账款

    应收分保合同准备金

    应收利息                                                   2,941,594.94                205,402.28

    应收股利

    其他应收款                                            123,308,326.61             288,820,335.42

    买入返售金融资产

    存货                                                  308,848,995.61             272,364,591.19

    划分为持有待售的资产

    一年内到期的非流动资产                                     6,850,879.29               7,764,857.22

    其他流动资产                                           65,176,945.59                 40,789,464.54

流动资产合计                                             1,754,057,864.99           2,057,833,576.04

非流动资产:

    发放贷款及垫款



                                              第 11 页
  哈尔滨誉衡药业股份有限公司


    可供出售金融资产                             315,013,606.80      25,273,136.80

    持有至到期投资

    长期应收款

    长期股权投资                                 130,667,209.45     129,405,380.72

    投资性房地产

    固定资产                                    1,677,918,811.98   1,540,501,564.12

    在建工程                                     120,515,567.38     104,447,512.91

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                                     433,130,468.02     431,244,226.33

    开发支出                                      65,291,970.77      51,037,801.12

    商誉                                        3,692,048,683.27   3,623,156,883.80

    长期待摊费用                                  20,769,607.75      19,723,057.78

    递延所得税资产                                27,084,225.37      24,387,914.63

    其他非流动资产                               200,757,879.66     305,670,020.07

非流动资产合计                                  6,683,198,030.45   6,254,847,498.28

资产总计                                        8,437,255,895.44   8,312,681,074.32

流动负债:

    短期借款                                    1,700,000,000.00   1,699,000,000.00

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据                                        1,450,000.00     91,870,932.61

    应付账款                                     142,537,404.62      95,480,858.12

    预收款项                                     116,384,329.29     125,586,975.81

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                                    4,829,440.46       7,227,946.40

    应交税费                                      81,044,749.24      86,126,735.86




                                     第 12 页
  哈尔滨誉衡药业股份有限公司


    应付利息                                  2,769,531.14       2,619,305.56

    应付股利                                84,705,672.75      11,393,210.00

    其他应付款                             223,554,711.49     246,513,163.58

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款

    划分为持有待售的负债

    一年内到期的非流动负债                1,097,227,078.96   1,618,630,463.16

    其他流动负债

流动负债合计                              3,454,502,917.95   3,984,449,591.10

非流动负债:

    长期借款                               961,008,334.50     300,000,000.00

    应付债券

      其中:优先股

               永续债

    长期应付款                              33,340,000.00     456,548,563.61

    长期应付职工薪酬

    专项应付款                                1,952,713.13       1,953,568.23

    预计负债

    递延收益                                49,980,187.93      39,042,699.50

    递延所得税负债                          32,562,674.85      33,277,485.92

    其他非流动负债                          11,796,867.08      12,414,000.30

非流动负债合计                            1,090,640,777.49    843,236,317.56

负债合计                                  4,545,143,695.44   4,827,685,908.66

所有者权益:

    股本                                  2,198,290,350.00    733,009,500.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                               339,638,971.85    1,063,791,333.73

    减:库存股                                1,659,876.08       4,328,082.48

    其他综合收益

    专项储备



                               第 13 页
   哈尔滨誉衡药业股份有限公司


    盈余公积                                                    147,520,681.77             147,520,681.77

    一般风险准备

    未分配利润                                                 1,117,151,780.98           1,475,328,271.47

归属于母公司所有者权益合计                                     3,800,941,908.52           3,415,321,704.49

    少数股东权益                                                 91,170,291.48                69,673,461.17

所有者权益合计                                                 3,892,112,200.00           3,484,995,165.66

负债和所有者权益总计                                           8,437,255,895.44           8,312,681,074.32

法定代表人:朱吉满                     主管会计工作负责人:刁秀强                 会计机构负责人:刘文才


2、母公司资产负债表

                                                                                                   单位:元

                   项目                             期末余额                       期初余额

流动资产:

    货币资金                                                    417,929,740.42             301,982,833.79

    以公允价值计量且其变动计入当期损
益的金融资产

    衍生金融资产

    应收票据                                                       6,338,701.20                8,025,188.18

    应收账款                                                       2,437,911.57               43,467,657.22

    预付款项                                                     37,157,616.37                17,271,662.64

    应收利息                                                       2,941,594.94                  45,253.28

    应收股利                                                    191,195,328.74                88,500,000.00

    其他应收款                                                  888,739,531.93             805,611,531.56

    存货                                                         37,959,970.74                32,126,139.34

    划分为持有待售的资产

    一年内到期的非流动资产                                         1,940,057.61                 740,996.47

    其他流动资产                                                   9,952,470.07                5,196,193.09

流动资产合计                                                   1,596,592,923.59           1,302,967,455.57

非流动资产:

    可供出售金融资产                                            130,340,796.80                11,300,796.80

    持有至到期投资

    长期应收款

    长期股权投资                                               5,577,642,864.13           5,415,209,535.40

    投资性房地产



                                                   第 14 页
  哈尔滨誉衡药业股份有限公司


    固定资产                                       490,252,232.18     465,385,169.81

    在建工程                                          1,846,874.08     16,185,606.56

    工程物资

    固定资产清理

    生产性生物资产

    油气资产

    无形资产                                        96,684,046.78      76,502,733.02

    开发支出                                        12,356,132.08      12,356,132.08

    商誉

    长期待摊费用                                      5,563,542.85       1,981,437.85

    递延所得税资产                                    2,528,851.10       1,102,477.11

    其他非流动资产                                  95,042,201.40     165,710,232.48

非流动资产合计                                    6,412,257,541.40   6,165,734,121.11

资产总计                                          8,008,850,464.99   7,468,701,576.68

流动负债:

    短期借款                                      1,050,000,000.00   1,100,000,000.00

    以公允价值计量且其变动计入当期损
益的金融负债

    衍生金融负债

    应付票据

    应付账款                                        39,667,350.45      33,970,040.05

    预收款项                                        42,292,224.73      26,228,006.53

    应付职工薪酬                                                          146,293.26

    应交税费                                        14,182,841.16      22,344,819.89

    应付利息                                          2,226,083.22       2,046,763.89

    应付股利                                        84,705,672.75        1,893,210.00

    其他应付款                                    1,082,293,363.64    852,170,151.35

    划分为持有待售的负债

    一年内到期的非流动负债                        1,035,079,578.96   1,495,076,920.96

    其他流动负债

流动负债合计                                      3,350,447,114.91   3,533,876,205.93

非流动负债:

    长期借款                                       800,000,000.00     300,000,000.00

    应付债券




                                       第 15 页
   哈尔滨誉衡药业股份有限公司


      其中:优先股

               永续债

    长期应付款                                            33,340,000.00                401,401,063.61

    长期应付职工薪酬

    专项应付款

    预计负债

    递延收益                                              23,690,083.40                 10,387,833.37

    递延所得税负债

    其他非流动负债

非流动负债合计                                           857,030,083.40                711,788,896.98

负债合计                                               4,207,477,198.31            4,245,665,102.91

所有者权益:

    股本                                               2,198,290,350.00                733,009,500.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                                             704,301,695.60            1,428,454,057.48

    减:库存股                                             1,659,876.08                  4,328,082.48

    其他综合收益

    专项储备

    盈余公积                                             147,520,681.77                147,520,681.77

    未分配利润                                           752,920,415.39                918,380,317.00

所有者权益合计                                         3,801,373,266.68            3,223,036,473.77

负债和所有者权益总计                                   8,008,850,464.99            7,468,701,576.68

法定代表人:朱吉满              主管会计工作负责人:刁秀强                 会计机构负责人:刘文才


3、合并本报告期利润表

                                                                                             单位:元

                 项目                   本期发生额                        上期发生额

一、营业总收入                                       734,361,228.36                    662,947,486.01

    其中:营业收入                                   734,361,228.36                    662,947,486.01

           利息收入

           已赚保费

           手续费及佣金收入



                                            第 16 页
   哈尔滨誉衡药业股份有限公司


二、营业总成本                               514,879,387.21      467,061,704.28

    其中:营业成本                           295,394,461.19      241,269,147.66

             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额

             提取保险合同准备金净额

             保单红利支出

             分保费用

             营业税金及附加                       9,457,402.36     8,299,595.31

             销售费用                            62,148,550.83    85,564,145.94

             管理费用                        122,150,176.26      108,073,243.31

             财务费用                            25,114,620.92    23,025,997.47

             资产减值损失                          614,175.65       829,574.59

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                                  6,123,700.58     1,715,831.58
列)

             其中:对联营企业和合营
企业的投资收益

         汇兑收益(损失以“-”号填
列)

三、营业利润(亏损以“-”号填列)           225,605,541.73      197,601,613.31

    加:营业外收入                               33,515,522.62    17,780,599.38

         其中:非流动资产处置利得                  119,573.02         16,631.82

    减:营业外支出                                1,271,354.78      262,029.32

         其中:非流动资产处置损失                  855,351.05        -38,762.28

四、利润总额(亏损总额以“-”号填
                                             257,849,709.57      215,120,183.37
列)

    减:所得税费用                               39,836,025.43    31,468,033.06

五、净利润(净亏损以“-”号填列)           218,013,684.14      183,652,150.31

    归属于母公司所有者的净利润               216,041,965.19      175,382,136.73

    少数股东损益                                  1,971,718.95     8,270,013.58

六、其他综合收益的税后净额

  归属母公司所有者的其他综合收益
的税后净额


                                      第 17 页
   哈尔滨誉衡药业股份有限公司


    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                            218,013,684.14                       183,652,150.31

    归属于母公司所有者的综合收益
                                                            216,041,965.19                       175,382,136.73
总额

    归属于少数股东的综合收益总额                              1,971,718.95                         8,270,013.58

八、每股收益:

    (一)基本每股收益                                             0.0983                               0.0798

    (二)稀释每股收益                                             0.0983                               0.0798

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。
法定代表人:朱吉满                    主管会计工作负责人:刁秀强                     会计机构负责人:刘文才


4、母公司本报告期利润表

                                                                                                       单位:元

                 项目                          本期发生额                           上期发生额

一、营业收入                                                126,107,546.45                       170,543,503.29

    减:营业成本                                             32,892,385.51                        49,255,497.81



                                                  第 18 页
   哈尔滨誉衡药业股份有限公司


         营业税金及附加                           2,034,029.34     2,864,034.75

         销售费用                                11,659,041.05    46,170,452.19

         管理费用                                55,666,851.10    51,742,219.92

         财务费用                                19,070,279.00    15,973,750.27

         资产减值损失                               -12,741.63      767,464.16

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填
                                             191,387,530.22       93,648,671.40
列)

         其中:对联营企业和合营企
业的投资收益

二、营业利润(亏损以“-”号填列)           196,185,232.30       97,418,755.59

    加:营业外收入                                1,662,898.65     8,870,245.38

         其中:非流动资产处置利得                                   383,761.82

    减:营业外支出                                     879.95          1,537.00

         其中:非流动资产处置损失                      879.95              0.00

三、利润总额(亏损总额以“-”号填
                                             197,847,251.00      106,287,463.97
列)

    减:所得税费用                                2,895,178.52     1,409,658.44

四、净利润(净亏损以“-”号填列)           194,952,072.48      104,877,805.53

五、其他综合收益的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益



                                      第 19 页
   哈尔滨誉衡药业股份有限公司


           4.现金流量套期损益的有
效部分

           5.外币财务报表折算差额

           6.其他

六、综合收益总额                                           194,952,072.48                 104,877,805.53

七、每股收益:

    (一)基本每股收益                                             0.0887                        0.0477

    (二)稀释每股收益                                             0.0887                        0.0477

法定代表人:朱吉满                    主管会计工作负责人:刁秀强              会计机构负责人:刘文才


5、合并年初到报告期末利润表

                                                                                                单位:元

                 项目                         本期发生额                     上期发生额

一、营业总收入                                          2,071,429,028.58              1,927,552,868.07

    其中:营业收入                                      2,071,429,028.58              1,927,552,868.07

           利息收入

           已赚保费

           手续费及佣金收入

二、营业总成本                                          1,472,563,512.05              1,337,580,876.55

    其中:营业成本                                         852,208,256.00                 699,588,980.68

           利息支出

           手续费及佣金支出

           退保金

           赔付支出净额

           提取保险合同准备金净额

           保单红利支出

           分保费用

           营业税金及附加                                    26,053,025.13                 25,951,004.42

           销售费用                                        162,482,911.07                 258,382,631.54

           管理费用                                        352,785,068.57                 292,604,197.69

           财务费用                                          75,710,298.24                 60,156,286.25

           资产减值损失                                       3,323,953.04                   897,775.97

    加:公允价值变动收益(损失以
“-”号填列)

         投资收益(损失以“-”号填                          10,587,623.36                  4,313,175.54


                                                  第 20 页
  哈尔滨誉衡药业股份有限公司


列)

         其中:对联营企业和合营企
业的投资收益

         汇兑收益(损失以“-”号填
列)

三、营业利润(亏损以“-”号填列)           609,453,139.89      594,285,167.06

    加:营业外收入                               56,686,364.34    31,529,278.16

         其中:非流动资产处置利得                  167,262.80       520,678.35

    减:营业外支出                                4,649,247.02      424,565.39

         其中:非流动资产处置损失                 2,973,305.93        70,765.26

四、利润总额(亏损总额以“-”号填
                                             661,490,257.21      625,389,879.83
列)

    减:所得税费用                               97,160,604.90   101,075,260.71

五、净利润(净亏损以“-”号填列)           564,329,652.31      524,314,619.12

    归属于母公司所有者的净利润               557,832,822.01      499,076,807.55

    少数股东损益                                  6,496,830.30    25,237,811.57

六、其他综合收益的税后净额

  归属母公司所有者的其他综合收益
的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分




                                      第 21 页
   哈尔滨誉衡药业股份有限公司


             5.外币财务报表折算差额

             6.其他

  归属于少数股东的其他综合收益的
税后净额

七、综合收益总额                                             564,329,652.31                      524,314,619.12

    归属于母公司所有者的综合收益
                                                             557,832,822.01                      499,076,807.55
总额

    归属于少数股东的综合收益总额                                6,496,830.30                      25,237,811.57

八、每股收益:

    (一)基本每股收益                                               0.2537                             0.2271

    (二)稀释每股收益                                               0.2537                             0.2271

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。
法定代表人:朱吉满                      主管会计工作负责人:刁秀强                   会计机构负责人:刘文才


6、母公司年初到报告期末利润表

                                                                                                       单位:元

                 项目                           本期发生额                          上期发生额

一、营业收入                                                 339,633,788.70                      446,941,285.80

    减:营业成本                                               87,151,697.76                     130,895,597.54

           营业税金及附加                                       5,650,354.05                       7,521,358.25

           销售费用                                            28,381,713.61                     120,156,148.82

           管理费用                                          178,736,059.86                      126,711,578.76

           财务费用                                            57,353,394.38                      44,840,298.44

           资产减值损失                                          945,200.79                         997,561.08

    加:公允价值变动收益(损失以
“-”号填列)

           投资收益(损失以“-”号填
                                                             765,665,218.04                      360,144,846.01
列)

           其中:对联营企业和合营企
业的投资收益

二、营业利润(亏损以“-”号填列)                           747,080,586.29                      375,963,588.92

    加:营业外收入                                              2,412,194.82                      11,974,396.47

           其中:非流动资产处置利得                                     0.00                        383,761.82

    减:营业外支出                                               953,394.53                           25,907.77

           其中:非流动资产处置损失                               53,394.49                            9,162.62



                                                    第 22 页
   哈尔滨誉衡药业股份有限公司


三、利润总额(亏损总额以“-”号填
                                                           748,539,386.58                 387,912,077.62
列)

    减:所得税费用                                           -2,010,024.31                  7,455,157.51

四、净利润(净亏损以“-”号填列)                         750,549,410.89                 380,456,920.11

五、其他综合收益的税后净额

    (一)以后不能重分类进损益的
其他综合收益

             1.重新计量设定受益计划
净负债或净资产的变动

             2.权益法下在被投资单位
不能重分类进损益的其他综合收益中
享有的份额

    (二)以后将重分类进损益的其
他综合收益

             1.权益法下在被投资单位
以后将重分类进损益的其他综合收益
中享有的份额

             2.可供出售金融资产公允
价值变动损益

             3.持有至到期投资重分类
为可供出售金融资产损益

             4.现金流量套期损益的有
效部分

             5.外币财务报表折算差额

             6.其他

六、综合收益总额                                           750,549,410.89                 380,456,920.11

七、每股收益:

    (一)基本每股收益                                             0.3414                        0.1731

    (二)稀释每股收益                                             0.3414                        0.1731

法定代表人:朱吉满                    主管会计工作负责人:刁秀强              会计机构负责人:刘文才


7、合并年初到报告期末现金流量表

                                                                                                单位:元

                 项目                         本期发生额                     上期发生额

一、经营活动产生的现金流量:

    销售商品、提供劳务收到的现金                        2,281,254,352.40              2,209,199,302.30

    客户存款和同业存放款项净增加


                                                  第 23 页
     哈尔滨誉衡药业股份有限公司




      向中央银行借款净增加额

      向其他金融机构拆入资金净增加


      收到原保险合同保费取得的现金

      收到再保险业务现金净额

      保户储金及投资款净增加额

      处置以公允价值计量且其变动计
入当期损益的金融资产净增加额

      收取利息、手续费及佣金的现金

      拆入资金净增加额

      回购业务资金净增加额

      收到的税费返还

      收到其他与经营活动有关的现金          551,590,521.45       671,041,568.76

经营活动现金流入小计                       2,832,844,873.85     2,880,240,871.06

      购买商品、接受劳务支付的现金          950,715,009.05       824,064,193.44

      客户贷款及垫款净增加额

      存放中央银行和同业款项净增加


      支付原保险合同赔付款项的现金

      支付利息、手续费及佣金的现金

      支付保单红利的现金

      支付给职工以及为职工支付的现
                                            247,720,493.13       188,515,024.90


      支付的各项税费                        373,422,359.11       377,586,272.36

      支付其他与经营活动有关的现金          688,113,769.32       890,051,130.82

经营活动现金流出小计                       2,259,971,630.61     2,280,216,621.52

经营活动产生的现金流量净额                  572,873,243.24       600,024,249.54

二、投资活动产生的现金流量:

      收回投资收到的现金                   3,507,818,013.54     3,494,094,767.12

      取得投资收益收到的现金                     3,771,679.89       4,308,408.42

      处置固定资产、无形资产和其他
                                                  576,544.01         703,939.00
长期资产收回的现金净额

      处置子公司及其他营业单位收到
                                                28,693,020.11
的现金净额

      收到其他与投资活动有关的现金              75,000,000.00


                                     第 24 页
   哈尔滨誉衡药业股份有限公司


投资活动现金流入小计                                 3,615,859,257.55             3,499,107,114.54

    购建固定资产、无形资产和其他
                                                      125,965,785.37               174,671,107.54
长期资产支付的现金

    投资支付的现金                                   3,807,778,483.54             3,519,651,400.00

    质押贷款净增加额

    取得子公司及其他营业单位支付
                                                     1,054,439,802.84             1,128,352,424.26
的现金净额

    支付其他与投资活动有关的现金                                                   295,840,000.00

投资活动现金流出小计                                 4,988,184,071.75             5,118,514,931.80

投资活动产生的现金流量净额                          -1,372,324,814.20            -1,619,407,817.26

三、筹资活动产生的现金流量:

    吸收投资收到的现金                                    15,000,000.00

    其中:子公司吸收少数股东投资
                                                          15,000,000.00
收到的现金

    取得借款收到的现金                               1,961,008,334.50             2,000,000,000.00

    发行债券收到的现金

    收到其他与筹资活动有关的现金                      133,804,846.61                49,000,000.00

筹资活动现金流入小计                                 2,109,813,181.11             2,049,000,000.00

    偿还债务支付的现金                               1,299,000,000.00              980,000,000.00

    分配股利、利润或偿付利息支付
                                                      189,463,927.60               139,444,916.56
的现金

    其中:子公司支付给少数股东的
                                                                                    10,648,500.00
股利、利润

    支付其他与筹资活动有关的现金                      175,641,024.00                68,815,201.14

筹资活动现金流出小计                                 1,664,104,951.60             1,188,260,117.70

筹资活动产生的现金流量净额                            445,708,229.51               860,739,882.30

四、汇率变动对现金及现金等价物的
                                                                   2.09                       1.96
影响

五、现金及现金等价物净增加额                          -353,743,339.36             -158,643,683.46

    加:期初现金及现金等价物余额                     1,017,919,279.57             1,071,101,367.31

六、期末现金及现金等价物余额                          664,175,940.21               912,457,683.85

法定代表人:朱吉满                 主管会计工作负责人:刁秀强             会计机构负责人:刘文才


8、母公司年初到报告期末现金流量表

                                                                                          单位:元




                                               第 25 页
     哈尔滨誉衡药业股份有限公司


                项目                 本期发生额                    上期发生额

一、经营活动产生的现金流量:

      销售商品、提供劳务收到的现金                442,128,098.99                481,969,855.12

      收到的税费返还

      收到其他与经营活动有关的现金            3,441,916,907.17              2,520,230,983.09

经营活动现金流入小计                          3,884,045,006.16              3,002,200,838.21

      购买商品、接受劳务支付的现金                 82,668,278.02                158,290,109.40

      支付给职工以及为职工支付的现
                                                   88,098,390.83                 54,300,241.98


      支付的各项税费                               56,646,733.90                 82,422,425.90

      支付其他与经营活动有关的现金            3,426,286,559.76              2,153,841,580.60

经营活动现金流出小计                          3,653,699,962.51              2,448,854,357.88

经营活动产生的现金流量净额                        230,345,043.65                553,346,480.33

二、投资活动产生的现金流量:

      收回投资收到的现金                      2,910,600,000.00              2,951,040,000.00

      取得投资收益收到的现金                      661,708,060.57                362,119,983.70

      处置固定资产、无形资产和其他
                                                     133,667.20                    497,900.00
长期资产收回的现金净额

      处置子公司及其他营业单位收到
                                                   35,000,000.00
的现金净额

      收到其他与投资活动有关的现金                 75,000,000.00

投资活动现金流入小计                          3,682,441,727.77              3,313,657,883.70

      购建固定资产、无形资产和其他
                                                   34,003,814.97                 73,774,259.40
长期资产支付的现金

      投资支付的现金                          3,012,640,000.00              2,967,070,000.00

      取得子公司及其他营业单位支付
                                              1,041,979,905.61              1,213,617,762.74
的现金净额

      支付其他与投资活动有关的现金                                               95,840,000.00

投资活动现金流出小计                          4,088,623,720.58              4,350,302,022.14

投资活动产生的现金流量净额                     -406,181,992.81             -1,036,644,138.44

三、筹资活动产生的现金流量:

      吸收投资收到的现金

      取得借款收到的现金                      1,350,000,000.00              1,350,000,000.00

      发行债券收到的现金

      收到其他与筹资活动有关的现金



                                        第 26 页
   哈尔滨誉衡药业股份有限公司


筹资活动现金流入小计                                  1,350,000,000.00                1,350,000,000.00

     偿还债务支付的现金                                900,000,000.00                   980,000,000.00

     分配股利、利润或偿付利息支付
                                                       157,675,120.21                   112,462,166.57
的现金

     支付其他与筹资活动有关的现金                      175,641,024.00                        66,342.93

筹资活动现金流出小计                                  1,233,316,144.21                1,092,528,509.50

筹资活动产生的现金流量净额                             116,683,855.79                   257,471,490.50

四、汇率变动对现金及现金等价物的
影响

五、现金及现金等价物净增加额                               -59,153,093.37              -225,826,167.61

     加:期初现金及现金等价物余额                      261,982,833.79                   605,448,454.91

六、期末现金及现金等价物余额                           202,829,740.42                   379,622,287.30

法定代表人:朱吉满                  主管会计工作负责人:刁秀强                会计机构负责人:刘文才


二、审计报告

第三季度报告是否经过审计
□ 是 √ 否
公司第三季度报告未经审计。


                                                                            哈尔滨誉衡药业股份有限公司
                                                                                    法定代表人:朱吉满
                                                                                二〇一六年十月二十二日




                                                第 27 页